title: Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients.
abstract: The pathogenesis of pulmonary edema that occurs during interleukin-2 therapy has often been attributed to an increase in pulmonary capillary permeability. However, renal insufficiency, fluid overload, and hypotension also develop in many patients. These manifestations of systemic toxicity may contribute to the development of pulmonary edema during therapy. Understanding the cause of pulmonary edema during interleukin-2 therapy could directly affect patients' care. Therefore, we reviewed the chest radiographs and clinical course of 54 patients who received high-dose interleukin-2 therapy and lymphokine-activated killer cells for advanced carcinoma. The type, frequency, and course over time of pulmonary abnormalities were recorded and correlated with clinical measures of renal function, fluid status, and blood pressure. Focal or diffuse parenchymal lung opacities were found on radiographs in 43 (80%) of 54 patients. Findings of interstitial pulmonary edema were most common, occurring in 76% of patients. Weight gain, hypotension, and elevation of the serum creatinine level were not associated statistically with interstitial edema. Diffuse air-space disease developed in 20% of patients. Focal consolidation, which was associated with positive central venous catheter cultures (p less than .03), developed in 28% of patients. Pleural effusion occurred in 48% of patients and was associated with all types of parenchymal disease. These data suggest that the frequent development of pulmonary edema during interleukin-2 therapy is not due to renal insufficiency, fluid overload, or hypotension, but is more likely the result of an interleukin-2-related increase in pulmonary capillary permeability.
authors.affiliation: Department of Radiology, University of California, San Francisco, School of Medicine 94143-0628.
authors.forename: R R
authors.initials: RR
authors.lastname: Saxon
authors.forename: J S
authors.initials: JS
authors.lastname: Klein
authors.forename: M H
authors.initials: MH
authors.lastname: Bar
authors.forename: P
authors.initials: P
authors.lastname: Blanc
authors.forename: G
authors.initials: G
authors.lastname: Gamsu
authors.forename: W R
authors.initials: WR
authors.lastname: Webb
authors.forename: F R
authors.initials: FR
authors.lastname: Aronson
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000493:pharmacokinetics; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology; D008875:Middle Aged; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000453:epidemiology; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology; D013902:Radiography, Thoracic; D012189:Retrospective Studies
chemical_list: D007376:Interleukin-2